Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…Background The current therapeutic antibodies and chimeric antigen receptor (CAR) T cells are capable of recognizing surface antigens, but not of intracellular proteins, thus limiting the target coverage for drug development. …”
Get full text

Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia by Haotian Ma, Zhifeng Yan, Runxia Gu, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang, Jianxiang Wang

Subjects: Get full text

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults by Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Coffey, Arend von Stackelberg, Semjon Willier, Brigitte Strahm, Christina Peters, Tobias Feuchtinger

“…Abstract Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. …”
Get full text

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor

“…Background Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and frequent inability to achieve cure with conventional chemotherapy. …”
Get full text

Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study by Jing Yang, Jing Zhang, Xinyu Wan, Jiaoyang Cai, Jiaoyang Cai, Tianyi Wang, Xiaomin Yang, Wenjie Li, Lixia Ding, Lili Song, Yan Miao, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang, Benshang Li

Subjects: Get full text

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy by Jinlan Long, Shufeng Xie, Wenjie Zhang, Weiyu Dou, Yixin Wang, Ruiheng Wang, Han Liu, Zhenshu Xu

Get full text

Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15 by Xin Xu, Shantan Reddy, Saleh Bhar, Frederic D Bushman, Amy N Courtney, Gabriel A Barragán, Gengwen Tian, Erica J Di Pierro, Leonid S Metelitsa, Antonino Montalbano, Hangjin Yu, Claudia Martinez Amador, Nisha Ghatwai, Michael S Wood, Deborah Schady, Aoife M Roche, David de la Cerda, Donald Williams Parsons, Andras Heczey

“…Here, we describe a case of lethal hyperleukocytosis in a patient with neuroblastoma treated on phase 1 clinical trial (NCT03294954) with autologous natural killer T cells (NKTs) expressing a GD2-specific chimeric antigen receptor and cytokine interleukin 15 (GD2-CAR.15). …”
Get full text

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)” by Vanessa Fairhurst, Randa Salah Gomaa Mahmoud, Toba Olatoye, Sylvester Sakilay

Get full text

An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk by Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang, Sihan Zhou, Xiuyuan Hao

Get full text

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma by Narendranath Epperla, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Kim Saverno

Subjects: Get full text

Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy by Jianyao Zeng, Yan Sun, Yan Sun, Yuan Fang, Xiaodie Wang, Qian Huang, Pingjing Zhang, Meiqi Shao, Pei Wang, Jingbo Cheng, Meng Di, Tao Liu, Qijun Qian, Qijun Qian, Qijun Qian

Subjects: Get full text

Targeting BCMA in multiple myeloma: designs, challenges, and future directions by Yi Hu, Yuetao Xie, Xiaodong Wang, Lufeng Yang, He Geng, Zugang Yi, Yao Zhang, Lin Ma, Fang Chen

Subjects: Get full text

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma by Jiaying Wu, Wanying Liu, Yang Cao, Yang Yang, Zhen Shang, Mi Zhou, Yicheng Zhang, Fankai Meng, Xiaojian Zhu, Yi Xiao

Subjects: Get full text

CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies by Fang Wang, Ruiqi Zhang, Zhaokai Zhou, Run Shi, Fu Peng, Yudi Xu, Shuai Yang, Zhan Wang, Pengpeng Zhang, Rui Tu, Chun Zhang, Xingchen Liu, Jun Cai

Subjects: Get full text

Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells by Yang Liu, Xiaoshuang Yuan, Xu Yang, Bo Yang, Guangyang Liu, Xiao Xu, Sanbin Wang, Zhixu He, Feiqing Wang, Yanju Li

Subjects: Get full text

Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells by Marat Khaliulin, Aygul Valiullina, Alexey Petukhov, Youyong Yuan, Sheila Spada, Emil Bulatov

Subjects: Get full text

CAR-T cells: prospective genetic engineering approach to orchestrate solid tumor in lung cancer by Angeline Felisca Tanujaya, Dhea Anggraini, Ahmad Dzulfikri Nurhan

Subjects: Get full text

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis by Federica Galvagno, Valeria Leuci, Annamaria Massa, Chiara Donini, Ramona Rotolo, Sonia Capellero, Alessia Proment, Letizia Vitali, Andrea Maria Lombardi, Valentina Tuninetti, Lorenzo D’Ambrosio, Alessandra Merlini, Elisa Vigna, Giorgio Valabrega, Luca Primo, Alberto Puliafito, Dario Sangiolo

Subjects: Get full text

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia by Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Delin Kong, Jia Geng, Alex H. Chang, He Huang, Yongxian Hu

Subjects: Get full text

In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma by Zhi Guo, Zhi Guo, Mingxin He, Ning Liu, Yiqing Yang, Rui Sun, Jianxun Wang, Qiang Wang

“…BackgroundChimeric antigen receptor T (CAR-T) cell therapy is more effective in relapsed or refractory diffuse large B cell lymphoma (DLBCL) than other therapies, but a high proportion of patients relapse after CAR-T cell therapy owing to antigen escape, limited persistence of CAR-T cells, and immunosuppression in the tumor microenvironment. …”
Get full text